AscrosMedical Robotics
Robotics for humans – rehabilitation that measures every movement
ascros is the medical line of a closed-loop rehabilitation platform for arms and legs. It is developed by Swissrehamed GmbH in Chur, Switzerland, on the same hardware as the sports line craPos.
The device
The ascros-test-bench
- Four drives: two for the arms, two for the legs
- Every drive is also a sensor: position, speed, torque
- Closed-loop control at 400 Hz, measured in the lab
- The phase between the limbs is measured, not commanded – the device follows the person
Research prototype in the Srm-Lab, Chur. Not CE marked, not FDA cleared, not available for sale.
Measured
What the device already delivers
Torque of all four limbs over three seconds, recorded in a manned run.
The platform
Any device with any game: ECP-UGC
The device reports what it can measure, the game reports what it needs, and the platform connects the two. The device stays unchanged.
Relatives send photos, voice messages and texts. The therapist decides what appears in which session, and the game shows it as a personal reward.
Developed in the Innosuisse project 44539.1 (2020–2022) with OST, SUPSI and FHGR. All rights with Swissrehamed. ecp-ugc.swissrehamed.ch
Indications
One core, two indication modules
Multiple sclerosis first
Clinical investigation with SUPSI planned; approval by the ethics committee and Swissmedic sought. Target: medical device under the EU MDR.
Stroke
A first FDA pre-submission was filed in 2025 and will be revised. Stroke is the indication for the US market.
Shared core: hardware, real-time control, risk file, software and data layer. Indications are modules on top.
Business model
Deep, not broad – capital-light, not capital-heavy
The rehabilitation robotics market has shown that owning devices and markets alone does not create value. ascros draws its own conclusions from it.
One real mechanism
A patent-protected closed-loop system instead of a collection of third-party devices.
Partners carry market access
Licences with quality agreements and design transfer – the rollout is not financed from own equity.
Evidence, not showcase
Clinical partners for genuine validation, and the loop from patient outcome to reimbursement in view from the start.
Organisation
Swissrehamed as the core – two planned steps towards the market
Swissrehamed GmbH
Switzerland. Holds the intellectual property and research and development, builds the quality system, and licenses the platform.
Ascros Inc.
Delaware, USA. FDA pathway, US clinical partnerships, reimbursement.
Ascros Europe GmbH
Distribution in Europe. The exact form will be agreed with a European partner.
Both companies are forward-integration steps. Their order follows the market: the US first, Europe first, or both in parallel.
Status
Where ascros stands, November 2026
Running today
- ascros-test-bench measuring at 400 Hz
- ECP-UGC platform services on a Swiss server
In development
- Connector from the ascros-test-bench to ECP-UGC
- Therapy and family interfaces back online
- Session data storage
Intellectual property
- EP 2 364 686 B1, granted 2015
- PCT/EP2024/076634, pending
Contact
Visit the ascros-test-bench in Chur
Swissrehamed GmbH
Roterturmstrasse 19
CH-7000 Chur, Switzerland
Joeri Gredig, CEE
joeri.gredig(at)swissrehamed.ch
+41 79 340 44 85
More: swissrehamed.ch · boutique.swissrehamed.ch (investors) · ecp-ugc.swissrehamed.ch